Bayer to invest 2 bln euros in drug production over next 3 years
March 31, 2022; 3:14 AM EDT
FRANKFURT, March 31 (Reuters) – German drugmaker Bayer (BAYGn.DE) said it would invest around 2 billion euros ($2.23 billion) at pharmaceutical manufacturing sites over the next three years, mainly to bolster production of biotechnology drugs as well as cell and gene therapies.
FILE PHOTO: A bridge is decorated with the logo of a Bayer AG, a German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay
The sites to be upgraded include Berkeley, California, as well as Berlin, Leverkusen and Bergkamen in Germany.
In addition, Bayer will transfer a manufacturing plant in Sao Paulo Cancioneiro, Brazil, as well as parts of the infrastructure and services at the German sites in Bergkamen, Wuppertal and Berlin to new operators.
($1 = 0.8956 euros)
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
